Study Evaluating SKI-606 (Bosutinib) In Advanced Malignant Solid Tumors

Exclusion Criteria

• •Use of any systemic antitumor agents or any investigational agent within 28 days before the first dose of test article is administered.
• •Prior exposure to SKI-606 or any other Src-kinase inhibitor, major surgery or radiotherapy within 14 days before the first dose of test article (recovery from previous surgery should be complete before day 1).
• •Active central nervous system (CNS) metastases, as indicated by clinical symptoms, cerebral edema, requirement for corticosteroids and/or progressive growth (Treated CNS metastases must be stable for \>= 2 weeks before day 1).
• •Other exclusion applies.